Key Takeaways Ovid Therapeutics rallies 39.2% after upbeat phase I study data for its epilepsy candidate, OV329.OV329 showed strong GABAergic activity, increasing neural inhibition and boosting brain GABA levels.The therapy was well tolerated, and OVID plans a phase IIa study in drug-resistant focal onset seizures.Shares of Ovid Therapeutics (OVID) rallied 39.2% primarily driven by the encouraging top-line data readout from an early-stage study of the company’s lead investigational candidate, OV329.The cand ...